# Aspen Neuroscience

Type: Company

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/aspen-neuroscience
Canonical HTML page: https://getbiobrief.com/entity/aspen-neuroscience

## Recent coverage (1 stories)

### Aspen Doses 15 Patients with Scalable iPSC Therapy, Eyes Phase 3 in Parkinson's
2026-07-21 22:30:47 · Sentiment: Bullish · Impact: 7/10 · Sources: 1

Aspen Neuroscience completed dosing in Cohorts 3 and 4 of its ASPIRO trial, bringing total treated patients to 15. The use of a commercial-ready, cryopreserved formulation signals manufacturing maturity and positions the autologous iPSC therapy for pivotal trials. This milestone could shake up the Parkinson's cell therapy race.
Full story: https://getbiobrief.com/story/aspen-neuroscience-sasineprocel-parkinsons-phase3-ready

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.